Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
An2 Therapeutics Inc. (ANTX) Insider Trading Activity
Healthcare • Biotechnology • 41 employees
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Total Value
$549,726.86
Total Shares
837,520
Average Trade Value
$14,466.50
Most Active Insider
Readnour Robin Shane
Total Activity: $415,521
Largest Single Transaction
$77,730
by Readnour Robin Shane on Nov 19, 2024
30-Day Activity
4 Transactions
Volume: 32,998 shares
Value: $40,000
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
| Apr 10, 2025 | 9,705 | $10,000 | 41,507 (+23.4%) | Grant | ||
| Apr 10, 2025 | 3,065 | $10,000 | 6,231 (+49.2%) | Grant | ||
| Apr 10, 2025 | 9,705 | $10,000 | 18,677 (+52.0%) | Grant | ||
| Apr 10, 2025 | 10,523 | $10,000 | 145,538 (+7.2%) | Grant | ||
|
Chief Development Officer
|
Feb 26, 2025 | 50,250 | $0 | 80,074 (+62.8%) | Grant | |
|
Chief Financial Officer
|
Feb 26, 2025 | 46,500 | $0 | 79,170 (+58.7%) | Grant | |
|
Chief Executive Officer
|
Feb 26, 2025 | 145,250 | $0 | 246,380 (+59.0%) | Grant | |
|
See Remarks
|
Feb 26, 2025 | 58,500 | $0 | 175,172 (+33.4%) | Grant | |
|
Chief Strategy Officer
|
Feb 26, 2025 | 28,000 | $0 | 61,313 (+45.7%) | Grant | |
|
Chief Development Officer
|
Jan 3, 2025 | 2,957 | $3,965 | 29,824 (-9.9%) | Sale | |
|
See Remarks
|
Jan 3, 2025 | 9,663 | $12,958 | 116,672 (-8.3%) | Sale | |
|
Chief Financial Officer
|
Jan 3, 2025 | 2,957 | $3,965 | 32,670 (-9.1%) | Sale | |
|
Chief Strategy Officer
|
Jan 3, 2025 | 2,029 | $2,721 | 33,313 (-6.1%) | Sale | |
| Dec 19, 2024 | 9,816 | $10,000 | 135,015 (+7.3%) | Grant | ||
| Dec 19, 2024 | 8,972 | $10,000 | 31,802 (+28.2%) | Grant | ||
| Dec 19, 2024 | 8,972 | $10,000 | 8,972 (+100.0%) | Grant | ||
| Dec 19, 2024 | 3,166 | $10,000 | 3,166 (+100.0%) | Grant | ||
| Dec 19, 2024 | 9,077 | $10,000 | 9,077 (+100.0%) | Grant | ||
| Dec 10, 2024 | 5,000 | $7,462 | 582,288 (+0.9%) | Purchase | ||
| Dec 10, 2024 | 5,000 | $7,468 | 652,573 (+0.8%) | Purchase | ||
| Dec 9, 2024 | 12,289 | $17,577 | 577,288 (+2.1%) | Purchase | ||
| Dec 9, 2024 | 18,483 | $26,407 | 647,573 (+2.9%) | Purchase | ||
| Dec 6, 2024 | 6,517 | $9,427 | 629,090 (+1.0%) | Purchase | ||
| Dec 6, 2024 | 12,711 | $18,367 | 564,999 (+2.2%) | Purchase | ||
| Nov 27, 2024 | 2,000 | $2,800 | 125,199 (+1.6%) | Purchase | ||
| Nov 27, 2024 | 25,000 | $35,423 | 552,288 (+4.5%) | Purchase | ||
| Nov 27, 2024 | 25,000 | $35,418 | 622,573 (+4.0%) | Purchase | ||
| Nov 26, 2024 | 12,500 | $17,418 | 527,288 (+2.4%) | Purchase | ||
| Nov 26, 2024 | 12,500 | $17,428 | 597,573 (+2.1%) | Purchase | ||
| Nov 20, 2024 | 25,000 | $29,000 | 585,073 (+4.3%) | Purchase | ||
| Nov 20, 2024 | 25,000 | $28,870 | 514,788 (+4.9%) | Purchase | ||
| Nov 19, 2024 | 5,000 | $5,050 | 123,199 (+4.1%) | Purchase | ||
| Nov 19, 2024 | 75,000 | $77,730 | 489,788 (+15.3%) | Purchase | ||
| Nov 19, 2024 | 75,000 | $77,528 | 560,073 (+13.4%) | Purchase | ||
|
Chief Executive Officer
|
Nov 18, 2024 | 50,000 | $49,970 | 1,065,766 (+4.7%) | Purchase | |
| Nov 18, 2024 | 20,000 | $19,996 | 118,199 (+16.9%) | Purchase | ||
|
See Remarks
|
Nov 4, 2024 | 31,500 | $0 | 126,335 (+24.9%) | Grant | |
|
Chief Strategy Officer
|
Nov 4, 2024 | 10,125 | $0 | 35,342 (+28.6%) | Grant |